anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medicine for treating white hair, which is composed of raw material with the following proportion by weight: 1 to 3 share of lilies, 1 to 4 shares of ecliptae herba, 1 to 4 shares of thin madder roots, 1 to 1.35 shares of glossy privet fruits, 1.5 to 4 shares of flos chrysanthemi from Hangzhou of China, 1.5 to 4 shares of raspberries, 0.5 to 2 shares of lotus stamens, 1 to 6 shares of medicated leavens and 0.5 to 3 shares of prepared radix glycyrrhiza. The present invention has the main functions of liver and kidney nourishing, lung heat clearance, the elimination of asthenic fever in vivo, hair blackening, vision acuity improvement, spirit tranquilization and nature restoration, and has the auxiliary functions of spleen and stomach conditioning, vital energy ventilation, tranquilization, gall calming and heat and toxic material clearance. The present invention adopts a comprehensive concept and carries out treatment based on differentiation of diseases. The present invention overcomes the defects of preparations which have the single function of kidney tonifying and blood nourishing, such as poor effectual effect, and simultaneously solves the problems that the long-term administration of patients easily causes the disorder of spleens and stomachs, appetite decline, metal depression, etc. The present invention is an effective prescription for treating leukotrichia, and is taken for a long term without toxic side effect. Clinical application shows that the curative rate of the present invention reaches more than 85%.
The invention relates to a medicated bath product and a preparation method thereof and belongs to the field of health-care life-nourishing products. The medicated bath product is formed by fermenting a mixture containing, by weight, 10-30% of pine tips and 70-90% of pine wood powder. The mixture further comprises, by weight, 60-65% of water. According to fermentation, the mixture is smashed and subjected to normal-temperature ultra-high-pressure sterilization and cooling, water is added for building a pile and fermentation, and then the pile is turned again for refermentation. The invention further provides a preparation method of the medicated bath product on the basis of the preceding fermentation steps. The invention further provides medicated bath pulp based on the medicated bath product, and the medicated bath product is protected to have application to preparing medicated bath articles with the effect of promoting the blood circulation to stop pain and/or preparing external medicine with the effect of promoting the blood circulation to stop pain. According to the medicated bath product, raw material sources are sufficient, composition matching is easy, the materials are environmentally friendly, cost is low, and the product has good effects of circulating the blood circulation, stopping pain, repelling wind, killing insects, adjusting the blood pressure and softening blood vessels. The preparation method is simple in process and easy to operate, and the obtained product has more remarkable effects.
Clear cell renal cell carcinoma (ccRCC) is characterized by dysregulated hypoxia signaling and a tumor microenvironment (TME) highly enriched in myeloid and lymphoid cells. Loss of the von Hippel Lindau (VHL) gene is a critical early event in ccRCC pathogenesis and promotes stabilization of HIF. Whether VHL loss in cancer cells affects immune cells in the TME remains unclear. Using Vhl WT and Vhl-KO in vivo murine kidney cancer Renca models, we found that Vhl-KO tumors were more infiltrated by immune cells. Tumor-associated macrophages (TAMs) from Vhl-deficient tumors demonstrated enhanced in vivo glucose consumption, phagocytosis, and inflammatory transcriptional signatures, whereas lymphocytes from Vhl-KO tumors showed reduced activation and a lower response to anti-programmed cell death 1 (anti-PD-1) therapy in vivo. The chemokine CX3CL1 was highly expressed in human ccRCC tumors and was associated with Vhl deficiency. Deletion of Cx3cl1 in cancer cells decreased myeloid cell infiltration associated with Vhl loss to provide a mechanism by which Vhl loss may have contributed to the altered immune landscape. Here, we identify cancer cell-specific genetic features that drove environmental reprogramming and shaped the tumor immune landscape, with therapeutic implications for the treatment of ccRCC.
The damage to hair during bleaching and dyeing with compounds yielding active oxygen, e.g. hydrogen peroxide, melamine perhydrate, percarbamide, perborates and persulphates, is reduced by treating it with a compound of the formula <FORM:0990660/D1-D2/1> in which X is -OH or -NH2, R1 is an aryl radical, an aliphatic radical with 1-5 carbon atoms or the radical <FORM:0990660/D1-D2/2> and R2 and R3 are hydrogen atoms or alkyl radicals with 1-5 carbon atoms, or a water-soluble salt thereof, e.g, the sodium, potassium, ammonium or ethanolamine salts.  The compound which may be applied to the hair before or during bleaching or dyeing as a solution, gel, cream, powder or paste, may also contain perfume oils, oxidation dyestuffs, thickeners, e.g. cellulose derivatives, polyvinyl pyrrolidone, polyacrylates, olginates and fatty alcohols, and anionic, cationic or nonionic wetting agents, e.g. fatty alcohol sulphates, alkyl sulphonates and condensation products of fatty alcohols with ethylene oxide in which the alkyl residues contain 12-18 carbon atoms, alkylbenzene sulphates and alkylpyridinium salts.  The treating composition preferably contains 0.01-10% by weight of the phosphorus-containing compound.
The last decade has seen remarkable progress in our understanding of disease biology of chronic lymphocytic leukaemia (CLL) and the development of novel targeted therapies. Randomised clinical trials have reported improved progression-free survival and overall survival with targeted therapies compared with chemoimmunotherapy, and thereby the role of chemoimmunotherapy in todays' era for treatment of CLL is limited. Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors, and CD20 monoclonal antibodies have been established as appropriate therapy options for patients with CLL, both as the first-line treatment and in the treatment of relapsed or refractory CLL. Several ongoing phase 3 trials are exploring different combinations of targeted therapies, and the results of these trials might change the treatment framework in first-line treatment of CLL. Non-covalent BTK inhibitors, chimeric antigen receptor T-cell therapy, and other therapeutic strategies are being investigated in relapsed CLL. Some of the therapies used in relapsed CLL, such as non-covalent BTK inhibitors, are now being pursued in earlier lines of therapy, including first-line treatment of CLL.
The invention discloses a purified traditional Chinese medicine gel for high-risk HPV persistent infection, which comprises traditional Chinese medicine components and an aqueous gel carrier; the Chinese medicinal components comprise radix Isatidis, herba Andrographitis, herba Scutellariae Barbatae, herba Lysimachiae Christinae, Curcumae rhizoma, cortex Phellodendri, radix Sophorae Flavescentis, radix Curcumae, Zingiberis rhizoma, Catechu, Alumen, and Borneolum Syntheticum. The weight ratio of the traditional Chinese medicine components to the aqueous gel carrier is 1: 1. The Chinese medicinal components are purified Chinese medicinal extract powder. The invention also provides the application of the medicine gel, and the medicine gel is used for preparing the medicament for vaginal administration. The invention also provides a preparation method of the medicament. The gel of the invention adopts purified traditional Chinese medicine components, has the advantages of safety, effectiveness, stable character, convenient use and the like, solves the problem of insufficient dosage of the traditional Chinese medicine in the vagina, and simultaneously overcomes the problems of sanitation, impurities, pollution and the like of the traditional Chinese medicine decoction pieces.
Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray: For Bencycloquidium Bromide Nasal Spray(90μg per spray), 1 spray on each nostril, 4times per day. For Mometasone Furoate Aqueous Nasal Spray (50μg per spray), 2 sprays on each nostril, 1 time per day. If there is an overlap between the two drugs, use Bencycloquidium Bromide Nasal Spray first, and then mometasone furoate nasal spray should be used after an interval of more than 30 minutes.
The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
Bleeding from esophageal and gastric cardia varices is the major life threatening complication in patients with portal hypertension. Patients with portal hypertension have a mortality rate of 30%-50% at the first episode of esophagogastric variceal rupture. The associated 1-year mortality rate is reported to be 75%. The ideal treatment for gastric varices should effectively control bleeding and improve the liver function to optimum levels. Although endoscopic treatments have showed great promise for esophageal varices, there is still controversy regarding the treatment of gastric varices. Hepatic encephalopathy remain a dominant problems after transjugular intrahepatic portosystemic shunt placement (TIPS) and surgical shunts. A meta-analysis has shown that the incidence of hepatic encephalopathy and mortality was increased significantly either in nonselective or selective shunt operations.

Esophagogastric decongestion and splenectomy with or without esophageal transaction were the fundamental operation performed in our department for patients with portal hypertension. Patients under the azygoportal devascularization methods revealed reduction of the encephalopathy as well as diminished rebleeding rates. The crucial point of the procedure is prevention of the brisk bleeding from the dilated vessels like enlarged azygoportal collaterals. Conventional hand-tied ligatures can become dislodged and represent a foreign body, and more important, it is tedious and time-consuming. The LigaSure vessel sealing system (Valleylab, Boulder, Colorado) is a bipolar electrosurgical device, sealing vessels up to 7 mm in diameter, by denaturing collagen and elastin within vessel wall and surrounding connective tissue. This device was tested, with excellent results, in different fields of surgery (gastrointestinal, hepatopancreatobiliary, urologic, gynecologic, laparoscopic, etc), as demonstrated by several recently published studies. Shamiyeh et al confirmed the reliability of LigaSure for the closure of the veins in laparoscopic azygoportal disconnection procedure on the portal hypertension porcine model in 2005, there was no intra- or post-operative bleeding and no conversion to open surgery, and when more than 2 mm far from the thermal energy source, no collateral damage of the solid tissue such as stomach could be detected.
PCT No. PCT/FR92/01178 Sec. 371 Date Sep. 1, 1994 Sec. 102(e) Date Sep. 1, 1994 PCT Filed Dec. 11, 1992 PCT Pub. No. WO93/12228 PCT Pub. Date Jun. 24, 1993The invention relates to a method for generating structural and functional diversity in a peptide sequence by randomly deleting and inserting nucleotides in a nucleotide sequence which codes for the peptide sequence. This method may be carried out by transfecting a cell preparation with vectors allowing expression of the Rag-1 and Rag-2 genes and optionally the terminal deoxynucleotidyl transferase gene, as well as with a vector including the nucleotide sequence which codes for the peptide sequence.\!
Non-suicidal self-injury has disseminated almost epidemically through the last decades in young persons. There is no evidence of any experimental treatment for non-suicidal self-injury in adolescents, superior to treatment as usual. Patients with stigmatizing illness such as non-suicidal self-injury may find internet-based interventions more acceptable. The study is a feasibility trial, with a randomization procedure in a parallel group design. Patients will be recruited from Child- and Adolescent Mental Health Services (age 13 to 17 years). The experimental intervention is internet-based, and therapist guided; ERITA consists of online Emotion Regulation Individual Therapy for Adolescents (ERITA) as add-on to treatment as usual. Treatment as usual is provided by multidisciplinary teams in nine outpatient clinics within Child and Adolescent Mental Health Services in the Capital Region of Denmark. Feasibility of recruitment and trial procedures will be monitored as well as explorative clinical outcomes.
Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6% by weight of an extract of Usnea barbata, containing 96% of usnic acid, and 40%  by weight of an extract of Hypericum perforatum, containing 39% of hyperforin, together.  The pharmaceutical composition leads to a potentiation of the anti-inflammatory and anti-microbial effects of the extracts and to stabilization of the hyperforin. The combination is suitable for the external and internal treatment of various skin diseases, in particular skin inflammations and skin ageing, and for the treatment of skin infections with pityrosporon yeast fungi, acne and rosacea.
Dialectical Behavior Therapy (DBT) is considered gold-standard therapy for individuals with borderline personality, and increasingly first line for addictions, coping deficits, and social instability. Participants will be asked to evaluate the integration of an Indigenous Knowledge Carrier (Elder) into a DBT program at an inner-city prenatal clinic. Patients will be pregnant or newly postpartum and qualify for DBT for routine mental health or substance associated indications. Therapy offerings will be customized to include traditional practices (ie: smudging, meditation) and teachings (ie: medicine wheel, 7 Sacred Teachings) along with standard, evidence-based content. The therapy will be co-delivered by the Elder, a perinatal psychiatrist and social worker trained in DBT. Evaluation of this modified program will be voluntary. The pre-interview guide is guided by an Appreciative Inquiry lens. The post-interview guide will be developed after analysis of the content from the pre-interview guide. Appreciative Inquiry is a qualitative research method which focuses on a strengths-based approach. The investigators will thematically analyze the data from the pre/post interviews into the predefined five stages of Appreciative Inquiry.

The investigators will utilize the Methods for Patient and Public Engagement Guide to map our research stage, level, and method of engagement. These stages include preparing for execution, data collection, data analysis, dissemination, implementation, and evaluation. Within each of these stages there are various engagement levels (consult, collaborate and partner representative) and then various methods of engagement (appreciative inquiry, discussion groups, consultations etc.) With this stepwise approach, the investigators will identify outcomes-measures that are meaningful to the population served via patient feedback.
Migraine is an intense, throbbing headache. You may have pain on one or both sides of your head. You may have nausea and vomiting, and be sensitive to light and noise. The pain and symptoms of a migraine headache can be worse than a common headache. Some women get migraines around the time of their menstrual period. Some people have visual symptoms before the headache, such as flashing lights or wavy lines, called an aura.
Corticobasal syndrome is generally considered to be a sporadic condition. There are familial and isolated genetic cases, associated with GRN, MAPT, c9orf72 or PNRP variants. Some reports implicate other genes: LRRK2, CHMP2B, GBA, CYP27A1, PSEN1, APP, TARDBP and TBK1. Here, we report a case of a patient carrying a SQSTM1 Pro392Leu variant. We report a 57-year-old right-handed-woman with a history of progressive speech impairment, marked right side rigidity and bradykinesia, with rest tremor and stimulus sensitive myoclonus. She had predominantly right-sided apraxia. She had right side agraphestesia and astereognosis. MRI showed asymmetrical left frontotemporoparietal atrophy. DaTSCAN showed predominantly left involvement, PiB-PET was negative. CSF NfL was of 9356.5pg/mL. She carried a heterozygous variant P392L in SQSTM1. This case report expands the spectrum of phenotypes associated with SQSTM1 pathogenic variants. It also expands the list of genes associated with corticobasal syndrome, supporting the involvement of the ubiquitin-proteasome system in this condition.
BACKGROUND: While theoretical models have established the bidirectional relationship between health and wellbeing of parents and children with chronic health conditions (CHCs), previous work has predominantly emphasised the impact of parent functioning on child outcomes. This study examines how quality of life (QoL) domains in children with CHCs are associated with unmet supportive care needs (SCN) of their parents and explores whether these associations vary by health condition.
METHOD: Parents of children with congenital heart disease (CHD), type 1 diabetes (T1D) and cancer diagnosed before the age of 12 years and receiving treatment within the last 5 years were eligible. Parents recruited through charity organisations and social media platforms completed a secure, online survey via Qualtrics. The PedsQL examined child QoL across four dimensions: physical, emotional, social and school functioning. A 34-item survey assessed parents' unmet SCN in the previous month across six need domains (e.g., care and informational). Linear regressions examined associations between child QoL and unmet SCN domains and moderation analyses determined whether associations varied as a function of CHC.
RESULTS: The study included 186 parents (age range 25-56 years) of children diagnosed with various CHCs (52% CHD; 27% T1D, 21% cancer). The child's emotional functioning was inversely related to all unmet SCN domains, social functioning was inversely related to three domains (physical and social; support; financial), school functioning was inversely related to two domains (physical and social; care), and child's physical functioning was not associated with any SCN domains. Only the association between child school functioning and unmet care needs was significantly moderated by CHC type (p < 0.05).
CONCLUSION: Poorer emotional functioning in children with a CHC is a key factor in determining parents unmet SCN. Larger studies are required to replicate these findings and inform design of interventions addressing QoL and unmet SCN in families of children with common CHCs.
Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept (with Thymoglobulin and corticosteroids) and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.
Mild traumatic brain injury (mTBI), often called concussion, is a prevalent condition that can have significant implications for people's health, functioning and well-being. Current clinical practice relies on self-reported symptoms to guide decision-making regarding return to sport, employment, and education. Unfortunately, reliance on subjective evaluations may fail to accurately reflect the resolution of neuropathology, exposing individuals with mTBI to an increased risk of further head trauma. No objective technique currently exists to assess the microstructural alterations to brain tissue which characterise mTBI. MRI-based T2 relaxation is a quantitative imaging technique that is susceptible to detecting fluid properties in the brain and is hypothesised to indicate neuroinflammation. This study aimed to investigate the potential of individual-level T2 relaxometry to evaluate cellular damage from mTBI. 20 male participants with acute sports-related mTBI (within 14 days post-injury) and 44 healthy controls were recruited for this study. Each mTBI participant's voxel-wise T2 relaxometry map was analysed against healthy control averages using a voxel-wise z-test with false discovery rate correction. Five participants were re-scanned after clinical recovery and results were compared to their acute T2 relaxometry maps to assess reduction in potential neuroinflammation. T2 relaxation times were significantly increased in 19/20 (95 %) mTBI participants compared to healthy controls, in regions including the hippocampus, frontal cortex, parietal cortex, insula, cingulate cortex and cerebellum. Results suggest the presence of increased cerebral fluid in individuals with mTBI. Longitudinal results indicated a reduction in T2 relaxation for all five participants, indicating a possible resolution over time. This research highlights the potential of individual-level T2 relaxometry MRI as a non-invasive method for assessing subtle brain pathology in mTBI. Identifying and monitoring changes in the fluid content in the brain could aid in predicting recovery and developing individualised treatment plans for individuals with mTBI. Future research should validate this measure with other markers of inflammation (e.g. from blood biomarkers) to test whether T2-relaxometry is related to subtle brain inflammation in mTBI. In addition, future research should utilise larger control groups to establish normative ranges and compute robust z-score analyses.
The efficacy of FRAGMIN in neonatal patients is based on a retrospective, non-interventional, multi-center study in 16 neonatal patients with deep vein thrombosis. Of the 16 total patients, the median gestational age was 39.1 weeks and median age at first FRAGMIN dose was 13.5 days. Patients were treated with FRAGMIN for up to 3.5 months, with starting doses determined by weight. 

The efficacy of FRAGMIN was established by the achievement of VTE resolution and/or completion of FRAGMIN treatment and was supported by the number of patients with lack of VTE progression or new VTE. 

The efficacy population included neonatal patients who completed a treatment course of FRAGMIN and/or achieved VTE resolution. The median starting dose of FRAGMIN and the median dose (units/kg) required to achieve a therapeutic anti-Xa level during the dose adjustment period are presented in Table 21. Therapeutic anti-Xa levels were documented for 8 of the 16 patients. 

At the end of follow-up, resolution of the baseline VTE was documented for 4 patients (25%). No patients were reported to have either partial regression of the VTE or a new VTE. Of the remaining 12 patients, 1 patient (6%) switched to another anticoagulant after 3 days for an unknown reason (no adverse events related to FRAGMIN were documented) and 11 patients (69%) were reported to have completed their course of therapy.